Intellipharmaceutics International Inc. (OTCPK: IPCI.Q)
Health Care · Pharmaceuticals · CA
$0.00
— today · 0.0% 1Y
Intellipharmaceutics International Inc. (OTCPK: IPCI.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $33.00 and employs 11 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Intellipharmaceutics International Inc. across four factors: quality 10/100, value 39/100. Its strongest factor is value.
IPCI.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.00
- Revenue (TTM)
- $904.95K
- P/E
- —
- EPS
- -0.09
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 33.09M
- Employees
- 11
- Next earnings
- —
About Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
- ISIN
- CA4581733090
- Founded
- 1998
- Listed since
- Jul 22, 1999
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Baudax Bio, Inc.OTCPK: BXRX.Q | $52.00 | $0.00 | — |
| Core One Labs Inc.OTCPK: CLAB.F | $47.00 | $0.00 | — |
| Claritas Pharmaceuticals, Inc.OTCPK: CLAZ.F | $38.00 | $0.00 | — |
| Maven Brands Inc.OTCPK: TRLF.F | $35.00 | $— | — |
| New Leaf Ventures IncOTCPK: NLVV.F | $30.00 | $0.00 | — |
| Verde Science, Inc.OTCPK: VRCI | $24.00 | $— | — |
| Sienna Biopharmaceuticals, Inc.OTCPK: SNNA.Q | $23.00 | $0.00 | — |
| Regnum Corp.OTCPK: RGMP | $23.00 | $— | — |
Figures last refreshed Oct 11, 2026.